FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W44237636> ?p ?o ?g. }

• W44237636 endingPage "1611.e4" @default.
• W44237636 startingPage "1604" @default.
• W44237636 abstract "Objective To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). Design Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. Participants We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. Methods Participants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. Main Outcome Measures Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). Results Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P<0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53–0.83 and OR, 0.60; 95% CI, 0.47–0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71–1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57–0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. Conclusions Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation. Financial Disclosure(s) The authors have no proprietary or commercial interest in any of the materials discussed in this article. To describe the long-term effects (10 years) of the Age-Related Eye Disease Study (AREDS) formulation of high-dose antioxidants and zinc supplement on progression of age-related macular degeneration (AMD). Multicenter, randomized, controlled, clinical trial followed by an epidemiologic follow-up study. We enrolled 4757 participants with varying severity of AMD in the clinical trial; 3549 surviving participants consented to the follow-up study. Participants were randomly assigned to antioxidants C, E, and β-carotene and/or zinc versus placebo during the clinical trial. For participants with intermediate or advanced AMD in 1 eye, the AREDS formulation delayed the progression to advanced AMD. Participants were then enrolled in a follow-up study. Eye examinations were conducted with annual fundus photographs and best-corrected visual acuity assessments. Medical histories and mortality were obtained for safety monitoring. Repeated measures logistic regression was used in the primary analyses. Photographic assessment of progression to, or history of treatment for, advanced AMD (neovascular [NV] or central geographic atrophy [CGA]), and moderate visual acuity loss from baseline (≥15 letters). Comparison of the participants originally assigned to placebo in AREDS categories 3 and 4 at baseline with those originally assigned to AREDS formulation at 10 years demonstrated a significant (P<0.001) odds reduction in the risk of developing advanced AMD or the development of NV AMD (odds ratio [OR], 0.66, 95% confidence interval [CI], 0.53–0.83 and OR, 0.60; 95% CI, 0.47–0. 78, respectively). No significant reduction (P = 0.93) was seen for the CGA (OR, 1.02; 95% CI, 0.71–1.45). A significant reduction (P = 0.002) for the development of moderate vision loss was seen (OR 0.71; 95% CI, 0.57–0.88). No adverse effects were associated with the AREDS formulation. Mortality was reduced in participants assigned to zinc, especially death from circulatory diseases. Five years after the clinical trial ended, the beneficial effects of the AREDS formulation persisted for development of NV AMD but not for CGA. These results are consistent with the original recommendations that persons with intermediate or advanced AMD in 1 eye should consider taking the AREDS formulation." @default.
• W44237636 created "2016-06-24" @default.
• W44237636 creator A5013513958 @default.
• W44237636 creator A5028034153 @default.
• W44237636 creator A5057220376 @default.
• W44237636 creator A5088078791 @default.
• W44237636 creator A5088588454 @default.
• W44237636 creator A5090722258 @default.
• W44237636 creator A5090802305 @default.
• W44237636 date "2013-08-01" @default.
• W44237636 modified "2023-10-14" @default.
• W44237636 title "Long-Term Effects of Vitamins C and E, β-Carotene, and Zinc on Age-related Macular Degeneration" @default.
• W44237636 cites W1548644132 @default.
• W44237636 cites W1983563483 @default.
• W44237636 cites W2416146661 @default.
• W44237636 cites W2566154985 @default.
• W44237636 cites W2598520882 @default.
• W44237636 cites W2769264260 @default.
• W44237636 cites W71525847 @default.
• W44237636 doi "https://doi.org/10.1016/j.ophtha.2013.01.021" @default.
• W44237636 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3728272" @default.
• W44237636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23582353" @default.
• W44237636 hasPublicationYear "2013" @default.
• W44237636 type Work @default.
• W44237636 sameAs 44237636 @default.
• W44237636 citedByCount "214" @default.
• W44237636 countsByYear W442376362013 @default.
• W44237636 countsByYear W442376362014 @default.
• W44237636 countsByYear W442376362015 @default.
• W44237636 countsByYear W442376362016 @default.
• W44237636 countsByYear W442376362017 @default.
• W44237636 countsByYear W442376362018 @default.
• W44237636 countsByYear W442376362019 @default.
• W44237636 countsByYear W442376362020 @default.
• W44237636 countsByYear W442376362021 @default.
• W44237636 countsByYear W442376362022 @default.
• W44237636 countsByYear W442376362023 @default.
• W44237636 crossrefType "journal-article" @default.
• W44237636 hasAuthorship W44237636A5013513958 @default.
• W44237636 hasAuthorship W44237636A5028034153 @default.
• W44237636 hasAuthorship W44237636A5057220376 @default.
• W44237636 hasAuthorship W44237636A5088078791 @default.
• W44237636 hasAuthorship W44237636A5088588454 @default.
• W44237636 hasAuthorship W44237636A5090722258 @default.
• W44237636 hasAuthorship W44237636A5090802305 @default.
• W44237636 hasBestOaLocation W442376362 @default.
• W44237636 hasConcept C118487528 @default.
• W44237636 hasConcept C126322002 @default.
• W44237636 hasConcept C141071460 @default.
• W44237636 hasConcept C142724271 @default.
• W44237636 hasConcept C156957248 @default.
• W44237636 hasConcept C168563851 @default.
• W44237636 hasConcept C204787440 @default.
• W44237636 hasConcept C27081682 @default.
• W44237636 hasConcept C2776403814 @default.
• W44237636 hasConcept C2778257484 @default.
• W44237636 hasConcept C44249647 @default.
• W44237636 hasConcept C535046627 @default.
• W44237636 hasConcept C71924100 @default.
• W44237636 hasConceptScore W44237636C118487528 @default.
• W44237636 hasConceptScore W44237636C126322002 @default.
• W44237636 hasConceptScore W44237636C141071460 @default.
• W44237636 hasConceptScore W44237636C142724271 @default.
• W44237636 hasConceptScore W44237636C156957248 @default.
• W44237636 hasConceptScore W44237636C168563851 @default.
• W44237636 hasConceptScore W44237636C204787440 @default.
• W44237636 hasConceptScore W44237636C27081682 @default.
• W44237636 hasConceptScore W44237636C2776403814 @default.
• W44237636 hasConceptScore W44237636C2778257484 @default.
• W44237636 hasConceptScore W44237636C44249647 @default.
• W44237636 hasConceptScore W44237636C535046627 @default.
• W44237636 hasConceptScore W44237636C71924100 @default.
• W44237636 hasIssue "8" @default.
• W44237636 hasLocation W442376361 @default.
• W44237636 hasLocation W442376362 @default.
• W44237636 hasLocation W442376363 @default.
• W44237636 hasLocation W442376364 @default.
• W44237636 hasOpenAccess W44237636 @default.
• W44237636 hasPrimaryLocation W442376361 @default.
• W44237636 hasRelatedWork W2088011133 @default.
• W44237636 hasRelatedWork W2320987231 @default.
• W44237636 hasRelatedWork W2332234963 @default.
• W44237636 hasRelatedWork W2403423968 @default.
• W44237636 hasRelatedWork W2745923716 @default.
• W44237636 hasRelatedWork W2912568837 @default.
• W44237636 hasRelatedWork W2949424847 @default.
• W44237636 hasRelatedWork W3008321469 @default.
• W44237636 hasRelatedWork W4281630725 @default.
• W44237636 hasRelatedWork W4297541668 @default.
• W44237636 hasVolume "120" @default.
• W44237636 isParatext "false" @default.
• W44237636 isRetracted "false" @default.
• W44237636 magId "44237636" @default.
• W44237636 workType "article" @default.